Roche, a global leader in pharmaceuticals and diagnostics, recently unveiled two-year data from the pivotal Phase III Pagoda and Pavilion studies, showcasing the sustained efficacy and safety of Susvimo in treating two critical diabetic eye conditions: diabetic macular edema (DME) and diabetic retinopathy (DR). These conditions are among the leading causes of vision loss in […]
Roche (SIX: RO, ROG; OTCQX: RHHBY), a global leader in pharmaceuticals and diagnostics, announced a significant advancement in eye care with the U.S. Food and Drug Administration’s (FDA) approval of the Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS). This new formulation is approved for the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), […]
In a significant advancement in the treatment of eye diseases, the U.S. Food and Drug Administration (FDA) has approved Genentech’s Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). This approval marks a pivotal development […]
Rezolute, Inc. (Nasdaq: RZLT), a leader in the development of novel therapies for serious metabolic and rare diseases, today disclosed promising topline results from its Phase 2 clinical trial of RZ402, aimed at treating Diabetic Macular Edema (DME). The study highlighted significant improvements in central subfield thickness (CST), a critical biomarker in DME management, across […]
KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal anti-VEGF antibody biopolymer conjugate KSI-301 for the treatment of patients with treatment-naïve wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), has yielded promising additional safety, efficacy and durability data. According […]
Kodiak Sciences, a California-based biotechnology company, has recently completed patient enrollment for a phase 1 safety and tolerability study of its innovative retinal disease drug, KSI-301. This study marks a significant step in the clinical development of KSI-301, which is being tested primarily on patients with diabetic macular edema in the United States. The phase […]
The US FDA has approved lucentis (ranibizumab injection) for diabetic retinopathy treatment. Read the Lucentis FDA approval story in our pharma news updates section at DailyHealthNeeds.com.
Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA) for its lucentis (ranibizumab injection), making it the first medication approved in the U.S. for the treatment of all forms of diabetic retinopathy, whether accompanied by diabetic macular edema (DME) or not. Pioneering Treatment for Diabetic Retinopathy […]